Soleno Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	105.86	13.48	9.84	10.81	8.76	Upgrade
Research & Development	78.57	25.19	15.27	21.45	23.19	Upgrade
Operating Expenses	184.43	38.67	25.11	32.26	31.95	Upgrade
Operating Income	-184.43	-38.67	-25.11	-32.26	-31.95	Upgrade
Interest Expense	-0.23	-	-	-	-	Upgrade
Interest & Investment Income	12.05	2.58	0.3	0.11	0.01	Upgrade
Other Non Operating Income (Expenses)	-	-0.18	0.03	0.51	11.64	Upgrade
EBT Excluding Unusual Items	-172.61	-36.27	-24.78	-31.64	-20.3	Upgrade
Other Unusual Items	-3.24	-2.71	0.71	0.73	-4.34	Upgrade
Pretax Income	-175.85	-38.99	-24.07	-30.91	-24.64	Upgrade
Earnings From Continuing Operations	-175.85	-38.99	-24.07	-30.91	-24.64	Upgrade
Net Income	-175.85	-38.99	-24.07	-30.91	-24.64	Upgrade
Net Income to Common	-175.85	-38.99	-24.07	-30.91	-24.64	Upgrade
Shares Outstanding (Basic)	40	16	8	5	4	Upgrade
Shares Outstanding (Diluted)	40	16	8	5	4	Upgrade
Shares Change (YoY)	143.61%	96.40%	57.90%	27.39%	83.41%	Upgrade
EPS (Basic)	-4.38	-2.36	-2.87	-5.81	-5.90	Upgrade
EPS (Diluted)	-4.38	-2.36	-2.87	-5.81	-5.90	Upgrade
Free Cash Flow	-69.31	-24.94	-20.79	-27.79	-25.23	Upgrade
Free Cash Flow Per Share	-1.73	-1.51	-2.48	-5.23	-6.04	Upgrade
EBITDA	-182.44	-36.71	-23.15	-30.3	-30	Upgrade
D&A For EBITDA	1.99	1.96	1.96	1.96	1.95	Upgrade
EBIT	-184.43	-38.67	-25.11	-32.26	-31.95	Upgrade

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q